Evidence map›Paper›PMID 38235331›Full record

ArticleiScience2024

Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives.

Wafaa S Ramadan, Maha M Saber-Ayad, Ekram Saleh, Hajjaj H M Abdu-Allah, Abdel-Nasser A El-Shorbagi, Varsha Menon, Hamadeh Tarazi, Mohammad H Semreen, Nelson C Soares, Shirin Hafezi and 5 more

Abstract read
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Rational design of 2iScience · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wafaa S RamadanResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
Maha M Saber-AyadResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
Ekram SalehMedical Biochemistry and Molecular Biology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 12613, Egypt.
Hajjaj H M Abdu-AllahFaculty of Pharmacy, Assiut University, Assiut 16122, Egypt.
Abdel-Nasser A El-ShorbagiCollege of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.
Varsha MenonResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
Hamadeh TaraziCollege of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.
Mohammad H SemreenCollege of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.
Nelson C SoaresResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
Shirin HafeziResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
Thenmozhi VenkatakhalamResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
Samrein AhmedResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
Osamu KanieDepartment of Applied Biochemistry, Tokai University, 4-1-1 Kitakaname, Hiratsuka, Kanagawa 259-1292, Japan.
Rifat HamoudiResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
Raafat El-AwadyResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of hybrid compounds has been widely considered as a promising strategy to circumvent the difficulties that emerge in cancer treatment. The well-established strategy of adding acetyl groups to certain drugs has been demonstrated to enhance their therapeutic efficacy. Based on our previous work, an approach of accommodating two chemical entities into a single structure was implemented to synthesize new acetylated hybrids (

Indexed as

CancerComputational chemistryPharmaceutical science

Identifiers

PMID38235331
PMCPMC10792193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.